随着时间的推移，肿瘤与背景比的急剧增加允许[89ZR] ZR-PSMA-617 PET/CT在前列腺癌的早期生化复发中的肿瘤定位
Outstanding increase in tumor-to-background ratio over time allows tumor localization by [89Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer
影响因子:3.50000
分区:医学2区 / 肿瘤学2区 核医学2区
发表日期:2024 Oct 07
作者:
Caroline Burgard, Florian Rosar, Elena Larsen, Fadi Khreish, Johannes Linxweiler, Robert J Marlowe, Andrea Schaefer-Schuler, Stephan Maus, Sven Petto, Mark Bartholomä, Samer Ezziddin
摘要
使用前列腺特异性膜抗原（PSMA）标记为锆89（89ZR;半寿命〜78.41 H）标记的靶向的放射性示例的正电子发射断层扫描/计算机断层扫描/计算机断层扫描（PET/CT）显示出有望在bioatizic cress consect.bcrret crest.bcrret crret。 (median [minimum-maximum] prostate-specific antigen 0.52 (0.12-2.50 ng/mL) undergoing [89Zr]Zr-PSMA-617 PET/CT post-negative [68Ga]Ga-PSMA-11 PET/CT. PET/CT acquisition 1-h, 24-h, and 48-h post-injection of a median (minimum-maximum) [89ZR] ZR-PSMA-617示踪剂的活性为123（84-166）MBQ。[89ZR] ZR-PSMA-617 PET/CT完全检测到57个病变：18个局部复发，33个淋巴结转移，在30/38的PET pet（bcr）中（78％）在大多数情况下，从1-H的角度增加到24小时，随着时间的流逝，肿瘤与背景的比率显着增加，绝对增加了100次或以上的副作用。这很大一系列的组织病理学和成像验证提供了进一步的证据，表明[89ZR] ZR-PSMA-617 PET/CT是一种有益的成像模态，可以随着时间的推移将肿瘤与环境的比例显着增加。
Abstract
Positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-targeted radiotracers labeled with zirconium-89 (89Zr; half-life ~ 78.41 h) showed promise in localizing biochemical recurrence of prostate cancer (BCR) in pilot studies.Retrospective analysis of 38 consecutive men with BCR (median [minimum-maximum] prostate-specific antigen 0.52 (0.12-2.50 ng/mL) undergoing [89Zr]Zr-PSMA-617 PET/CT post-negative [68Ga]Ga-PSMA-11 PET/CT. PET/CT acquisition 1-h, 24-h, and 48-h post-injection of a median (minimum-maximum) [89Zr]Zr-PSMA-617 tracer activity of 123 (84-166) MBq.[89Zr]Zr-PSMA-617 PET/CT detected altogether 57 lesions: 18 local recurrences, 33 lymph node metastases, 6 bone metastases in 30/38 men with BCR (78%) and prior negative conventional PSMA PET/CT. Lesion uptake significantly increased from 1-h to 24-h and, in a majority of cases, from 24-h to 48-h. Tumor-to-background ratios significantly increased over time, with absolute increases of 100 or more. No side effects were noted. After [89Zr]Zr-PSMA-617 PET/CT-based treatment, prostate-specific antigen concentration decreased in all patients, becoming undetectable in a third of patients.retrospective, single center design; infrequent histopathological and imaging verification.This large series provides further evidence that [89Zr]Zr-PSMA-617 PET/CT is a beneficial imaging modality to localize early BCR. A remarkable increase in tumor-to-background ratio over time allows localization of tumor unidentified on conventional PSMA PET/CT.